S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
NYSEAMERICAN:IBIO

iBio (IBIO) Stock Price, News & Analysis

$1.24
-0.02 (-1.59%)
(As of 03/1/2024 ET)
Today's Range
$1.20
$1.26
50-Day Range
N/A
52-Week Range
$1.02
$52.00
Volume
79,653 shs
Average Volume
120,446 shs
Market Capitalization
$4.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About iBio

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

IBIO Stock Price History

IBIO Stock News Headlines

iBio (NYSEAMERICAN:IBIO) Upgraded to Hold by StockNews.com
iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Up 204.3% in February
See More Headlines
Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/09/2024
Today
3/02/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:IBIO
CIK
N/A
Employees
26
Year Founded
N/A

Profitability

Net Income
$-65,010,000.00
Pretax Margin
-41,546.00%

Debt

Sales & Book Value

Annual Sales
$2.38 million
Book Value
$2.64 per share

Miscellaneous

Free Float
3,445,000
Market Cap
$4.32 million
Optionable
N/A
Beta
-3.77
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Martin B. Brenner D.V.M. (Age 53)
    Ph.D., CEO & Chief Scientific Officer
    Comp: $577.31k
  • Mr. Felipe Duran (Age 44)
    Chief Financial Officer
    Comp: $1.07M
  • Stephen Kilmer
    Investor Relations Officer
  • Mr. Marc Banjak J.D.
    General Counsel
  • Mr. Robert B. Kay (Age 84)
    Interim Secretary & Interim Treasurer
    Comp: $92.69k














IBIO Stock Analysis - Frequently Asked Questions

Are investors shorting iBio?

iBio saw a increase in short interest in February. As of February 15th, there was short interest totaling 14,000 shares, an increase of 204.3% from the January 31st total of 4,600 shares. Based on an average trading volume of 201,800 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.4% of the shares of the stock are sold short.
View iBio's Short Interest
.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) announced its quarterly earnings results on Friday, February, 9th. The company reported ($2.42) earnings per share (EPS) for the quarter.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

Who are iBio's major shareholders?

iBio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%).

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:IBIO) was last updated on 3/3/2024 by MarketBeat.com Staff